Odyssey Therapeutics, Inc.
ODTX
$20.73
$0.010.05%
NASDAQ
| 06/30/2026 | 03/31/2026 | 06/30/2025 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | 959.00K | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | 959.00K | ||
| Cost of Revenue | 36.23M | -- | 30.23M | ||
| Gross Profit | -36.23M | -- | -29.27M | ||
| SG&A Expenses | 10.51M | 7.35M | 13.22M | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 46.74M | 39.67M | 43.45M | ||
| Operating Income | -46.74M | -39.67M | -42.49M | ||
| Income Before Tax | -52.80M | -38.20M | -41.21M | ||
| Income Tax Expenses | -8.00K | 63.00K | 30.00K | ||
| Earnings from Continuing Operations | -52.79M | -38.26M | -41.24M | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -52.79M | -38.26M | -41.24M | ||
| EBIT | -46.74M | -39.67M | -42.49M | ||
| EBITDA | -45.69M | -38.50M | -41.22M | ||
| EPS Basic | -1.74 | -6.77 | -29.54 | ||
| Normalized Basic EPS | -0.91 | -4.21 | -18.71 | ||
| EPS Diluted | -1.74 | -6.77 | -29.54 | ||
| Normalized Diluted EPS | -0.91 | -4.21 | -18.71 | ||
| Average Basic Shares Outstanding | 30.28M | 5.66M | 1.40M | ||
| Average Diluted Shares Outstanding | 30.28M | 5.66M | 1.40M | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||